Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: A role for nitric oxide

Journal of Immunology

Volumn 168, Issue 7, 2002, Pages 3419-3427

  Rivera, Johanna ^a   Mukherjee, Jean ^a   Weiss, Louis M ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2H1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; COLONY FORMATION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL;

EID: 0036533656     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.7.3419     Document Type: Article

References (64)

1. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection
2. Protective and nonprotective monoclonal antibodies to Cryptocccus neoformans originating from one B cell
3. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies
4. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection
5. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival
6. Cutting edge: Paradigm revisited: Antibody provides resistance to Listeria infection
7. Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection
8. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B
9. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans
10. Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria
11. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils
12. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody
13. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection
14. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity
15. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation
16. Cytokines and costimulatory molecules: Positive and negative regulation of the immune response to Cryptococcus neoformans
17. Nitric oxide and macrophage function
18. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism
19. Nitric oxide produced during murine listeriosis is protective
20. Cryptococcosis in the era of AIDS: 100 Years after the discovery of Cryptococcus neoformans
21. Oxidative killing of Cryptococcus neoformans by human neutrophils: Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates
22. Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effector of macrophage-mediated cytostasis
23. Human astrocytes inhibit the growth of Cryptococcus neoformans by a nitric oxide-mediated mechanism
24. A role for γ interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans
25. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas
26. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes
27. A galactoxylomannan antigen of Cryptococcus neoformans serotype A
28. Protective murine monoclonal antibodies to Cryptococcus neoformans
29. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice
30. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection
31. Mechanism of Pneumocystis carinii attachment to cultured rat alveolar macrophages
32. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
33. Urinary nitrate excretion in relation to murine macrophage activation: Influence of dietary L-arginine and oral NG-monomethyl-L-arginine
34. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide
35. Monoclonal antibody based ELISAs for cryptococcal polysaccharide
36. Involvement of nitric oxide in protecting mechanism during experimental cryptococcosis
37. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection
38. Antimicrobial proteins of murine macrophages
39. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro
40. Inhibition and killing of fungi by the polyamine oxidase-polyamine system
41. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase
42. Attenuated virulence of chitin-deficient mutants of Candida albicans
43. Tissue injury caused by deposition of immune complexes is L-arginine dependent
44. Nitric oxide synthases: Roles, tolls, and controls
45. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells
46. Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils in vivo and are ingested by the attracted granulocytes
47. The role of T lymphocytes in pulmonary microbial defense mechanisms
48. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection
49. Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro
50. Cytotoxic properties of the eosinophil major basic protein
51. Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix: A possible role for eosinophils in chronic inflammatory disorders of the lower respiratory tract
52. The role of eosinophils and neutrophils in inflammation
53. Eosinophils generate brominating oxidants in allergen-induced asthma
54. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: Role of IFN-γ in the induction of the nitric oxidesynthesizing pathway
55. Molecular basis of "suppressor" macrophages: Arginine metabolism via the nitric oxide synthetase pathway
56. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-γ and lipopolysaccharide
57. Immune complexes increase nitric oxide production by interferon-γ-stimulated murine macrophagelike J774.16 cells
58. TNF-α, nitric oxide and IFN-γ are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii
59. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice
60. Immunoregulatory mechanisms of T-cell-dependent shock induced by a bacterial superantigen in mice
61. + T cells are inducers and targets of nitric oxide produced by parasitized macrophages
62. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor
63. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response
64. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen